Journal
DRUG RESISTANCE UPDATES
Volume 8, Issue 3, Pages 147-162Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2005.04.007
Keywords
Candida; neonatal intensive care unit; antifungal therapy
Categories
Funding
- NIAID NIH HHS [T32 AI 052080] Funding Source: Medline
- NICHD NIH HHS [HD044799] Funding Source: Medline
- PHS HHS [K08 A1061149-01] Funding Source: Medline
Ask authors/readers for more resources
Advances in medical therapy have increased premature infant survival. A rise in Candida infections in neonatal intensive care units (NICUs) has followed. Once considered a contaminant, Candida is now recognized as a major cause of mortality and morbidity within these units. We will examine what is known about the epidemiology, risk factors and end-organ involvement of Candida infections with a focus on invasive disease. In addition, diagnostic alternatives to traditional blood culture, experience with antifungal agents for prophylaxis and therapeutic options, including newer antifungal agents, will be presented. (c) 2005 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available